Hercules Capital (HTGC) received a 'Buy' rating due to its resilient net asset value (NAV), strong dividend coverage at 117% in Q3, and leading return on equity (ROE) of 13%. The stock trades at a 1.35x NAV premium, supported by superior credit quality and minimal non-accrual loans compared to peers. While risks include rising funding costs and potential software loan defaults, the company's portfolio growth and insider buying support a positive outlook with likely continued supplemental dividends.
Hercules Capital's Q3 performance and valuation premium are presented here with Pluang's Financials-sector snapshot as of Nov 04, 2026 22:12 WIB: Among 142 priced US Financials stocks, 119 rose and 23 fell today. Notable movers include SEZL at USD 132.50 with a 1-day change of +8.23% and a Pluang order activity of 97% Sell / 3% Buy, AVAT at USD 0.94 up 8.05% with 24% Sell / 76% Buy, and UPST at USD 23.02 up 7.70% with 0% Sell / 100% Buy. The most notable figure is SEZL's 97% sell-side order activity.
The global AI accelerator market is projected to grow from $151 billion in 2025 to $443 billion by 2030, with a compound annual growth rate of about 24%. This expansion is fueled by the rise of generative AI, large language models, and increased inve...
A growing town replaced its inefficient IT request process of spreadsheets and emails with a centralized Microsoft Power Apps hub developed by eSoftware Associates. This hub integrates project intake, risk assessment, and PMO scoring into one platfor...
No7 Software has enhanced its Anchor Loyalty & Rewards app by integrating Shopify POS, allowing merchants to run a unified loyalty program across online stores and physical shops. Customers now maintain a single points balance, tier status, and refer...
Kelly Technology + Motion Recruitment, a division of Kelly Services, has been recognized as a Leader on Everest Group's 2026 U.S. IT Contingent Talent and Strategic Solutions PEAK Matrix® for its expertise in specialized IT staffing, consulting, and ...
Sutro Biopharma, a clinical-stage oncology company specializing in antibody drug conjugates (ADCs), announced its participation in several investor conferences in November and December 2026, including events hosted by Stifel, Truist Securities, UBS, ...
